Cantel Medical Competitors

NovoCure (NASDAQ:NVCR) and Cantel Medical (NYSE:CMD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for NovoCure and Cantel Medical, as provided by MarketBeat.

NovoCure presently has a consensus price target of $139.2857, suggesting a potential upside of 5.45%. Cantel Medical has a consensus price target of $71.50, suggesting a potential downside of 14.64%. Given NovoCure's stronger consensus rating and higher probable upside, research analysts plainly believe NovoCure is more favorable than Cantel Medical.

Earnings & Valuation

This table compares NovoCure and Cantel Medical's gross revenue, earnings per share and valuation.

Cantel Medical has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NovoCure and Cantel Medical's net margins, return on equity and return on assets.

Volatility & Risk

NovoCure has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Cantel Medical has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.

Institutional & Insider Ownership

71.1% of NovoCure shares are held by institutional investors. Comparatively, 95.0% of Cantel Medical shares are held by institutional investors. 5.1% of NovoCure shares are held by company insiders. Comparatively, 10.7% of Cantel Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cantel Medical beats NovoCure on 8 of the 14 factors compared between the two stocks.

Cantel Medical (NYSE:CMD) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Insider and Institutional Ownership

95.0% of Cantel Medical shares are owned by institutional investors. Comparatively, 88.2% of Penumbra shares are owned by institutional investors. 10.7% of Cantel Medical shares are owned by company insiders. Comparatively, 8.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cantel Medical and Penumbra, as reported by MarketBeat.com.

Cantel Medical currently has a consensus price target of $71.50, indicating a potential downside of 14.64%. Penumbra has a consensus price target of $279.00, indicating a potential upside of 2.56%. Given Penumbra's stronger consensus rating and higher probable upside, analysts clearly believe Penumbra is more favorable than Cantel Medical.

Earnings & Valuation

This table compares Cantel Medical and Penumbra's gross revenue, earnings per share and valuation.

Penumbra has lower revenue, but higher earnings than Cantel Medical. Cantel Medical is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cantel Medical and Penumbra's net margins, return on equity and return on assets.

Risk and Volatility

Cantel Medical has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Summary

Cantel Medical beats Penumbra on 9 of the 14 factors compared between the two stocks.

Hill-Rom (NYSE:HRC) and Cantel Medical (NYSE:CMD) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Hill-Rom and Cantel Medical's net margins, return on equity and return on assets.

Institutional and Insider Ownership

83.8% of Hill-Rom shares are owned by institutional investors. Comparatively, 95.0% of Cantel Medical shares are owned by institutional investors. 0.7% of Hill-Rom shares are owned by company insiders. Comparatively, 10.7% of Cantel Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Hill-Rom and Cantel Medical's revenue, earnings per share and valuation.

Hill-Rom has higher revenue and earnings than Cantel Medical. Hill-Rom is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Hill-Rom and Cantel Medical, as reported by MarketBeat.com.

Hill-Rom presently has a consensus price target of $121.00, indicating a potential upside of 7.14%. Cantel Medical has a consensus price target of $71.50, indicating a potential downside of 14.64%. Given Hill-Rom's stronger consensus rating and higher probable upside, research analysts clearly believe Hill-Rom is more favorable than Cantel Medical.

Volatility & Risk

Hill-Rom has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Cantel Medical has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.

Summary

Hill-Rom beats Cantel Medical on 9 of the 14 factors compared between the two stocks.

Cantel Medical (NYSE:CMD) and Globus Medical (NYSE:GMED) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Institutional & Insider Ownership

95.0% of Cantel Medical shares are held by institutional investors. Comparatively, 64.4% of Globus Medical shares are held by institutional investors. 10.7% of Cantel Medical shares are held by insiders. Comparatively, 25.6% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Cantel Medical and Globus Medical's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Cantel Medical and Globus Medical's gross revenue, earnings per share and valuation.

Globus Medical has lower revenue, but higher earnings than Cantel Medical. Globus Medical is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cantel Medical has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Cantel Medical and Globus Medical, as provided by MarketBeat.com.

Cantel Medical presently has a consensus price target of $71.50, indicating a potential downside of 14.64%. Globus Medical has a consensus price target of $66.40, indicating a potential downside of 0.90%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than Cantel Medical.

Summary

Globus Medical beats Cantel Medical on 9 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Cantel Medical (NYSE:CMD) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Profitability

This table compares Haemonetics and Cantel Medical's net margins, return on equity and return on assets.

Risk and Volatility

Haemonetics has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Cantel Medical has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Haemonetics and Cantel Medical, as reported by MarketBeat.

Haemonetics currently has a consensus price target of $144.80, suggesting a potential upside of 23.70%. Cantel Medical has a consensus price target of $71.50, suggesting a potential downside of 14.64%. Given Haemonetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Haemonetics is more favorable than Cantel Medical.

Valuation & Earnings

This table compares Haemonetics and Cantel Medical's gross revenue, earnings per share and valuation.

Haemonetics has higher earnings, but lower revenue than Cantel Medical. Haemonetics is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

96.2% of Haemonetics shares are held by institutional investors. Comparatively, 95.0% of Cantel Medical shares are held by institutional investors. 1.6% of Haemonetics shares are held by insiders. Comparatively, 10.7% of Cantel Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Haemonetics beats Cantel Medical on 10 of the 14 factors compared between the two stocks.

Cantel Medical (NYSE:CMD) and Inspire Medical Systems (NYSE:INSP) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

95.0% of Cantel Medical shares are held by institutional investors. Comparatively, 96.3% of Inspire Medical Systems shares are held by institutional investors. 10.7% of Cantel Medical shares are held by company insiders. Comparatively, 6.6% of Inspire Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cantel Medical and Inspire Medical Systems' top-line revenue, earnings per share (EPS) and valuation.

Cantel Medical has higher revenue and earnings than Inspire Medical Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Cantel Medical and Inspire Medical Systems, as provided by MarketBeat.

Cantel Medical currently has a consensus price target of $71.50, indicating a potential downside of 14.64%. Inspire Medical Systems has a consensus price target of $168.5455, indicating a potential downside of 22.84%. Given Cantel Medical's higher probable upside, equities analysts plainly believe Cantel Medical is more favorable than Inspire Medical Systems.

Volatility and Risk

Cantel Medical has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.

Profitability

This table compares Cantel Medical and Inspire Medical Systems' net margins, return on equity and return on assets.

Summary

Cantel Medical beats Inspire Medical Systems on 9 of the 14 factors compared between the two stocks.